View Document Preview and Link Document Date: 2014-10-09 14:55:47 Open Document File Size: 91,13 KB Share Result on Facebook
City New York / Paris / / Company Bayer / Genzyme Corporation / Sanofi Company / EMD Serono Inc. / / Country Mexico / France / United States / Brazil / Canada / Australia / / Event FDA Phase / Company Listing Change / / Facility Montreal Neurological Institute / McGill University / / IndustryTerm MS therapeutics / magnetic resonance imaging / pharmaceutical / healthcare / treatment of MS / therapeutic solutions / consumer healthcare / diabetes solutions / / MedicalCondition MS disease / rare and debilitating diseases / rare diseases / headache / inflammatory process / thyroid disease / nausea / serious infections / clinical disease / fatigue / multiple sclerosis / glomerulonephritis / lymphopenia / diarrhea / MS / pruritus / infections / sepsis / insomnia / disease / chills / immune thrombocytopenia / acute inflammation / diabetes / active disease / urticaria / dizziness / permanent brain injury / rash / / MedicalTreatment intravenous infusion / / Organization Department of Neurology and Neurosurgery / Montreal Neurological Institute / McGill University / FDA / European Union / 66th American Academy of Neurology / / Person David Meeker / Douglas Arnold / / Position global healthcare leader / President and CEO / / Product LemtradaTM / Rebif / European Union / Lemtrada / United States / / ProvinceOrState Mississippi / / Technology therapeutic solutions / MRI / magnetic resonance imaging / Neurosurgery / / URL www.genzyme.com / / SocialTag 
PRESS RELEASE Slowing of Brain Atrophy and Reductions in New Multiple Sclerosis Lesions Sustained at Three Years in Patients Treated with Genzyme’s LemtradaTM - Consistent effects seen across key MRI measures of disea